Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life

• Published in: Biochemistry (Easton) Vol. 56; no. 36; pp. 4860 - 4870
• Main Authors: Bukrinski, Jens T, Sønderby, Pernille, Antunes, Filipa, Andersen, Birgitte, Schmidt, Esben G. W, Peters, Günther H. J, Harris, Pernille
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 12.09.2017
• Subjects: Animals; Binding, Competitive; Female; Glucagon-Like Peptide 1 - chemistry; Half-Life; Histocompatibility Antigens Class I - chemistry; Humans; Mice; Protein Binding; Protein Conformation; Protein Stability; Receptors, Fc - chemistry; Recombinant Fusion Proteins - chemistry; Recombinant Fusion Proteins - pharmacokinetics; Serum Albumin - chemistry
• ISSN: 0006-2960; 1520-4995
• DOI: 10.1021/acs.biochem.7b00492

Glucagon-like peptide 1 (GLP-1) is a small incretin hormone stimulated by food intake, resulting in an amplification of the insulin response. Though GLP-1 is interesting as a drug candidate for the treatment of type 2 diabetes mellitus, its short plasma half-life of <3 min limits its clinical use. A strategy for extending the half-life of GLP-1 utilizes the long half-life of human serum albumin (HSA) by combining the two via chemical conjugation or genetic fusion. HSA has a plasma half-life of around 21 days because of its interaction with the neonatal Fc receptor (FcRn) expressed in endothelial cells of blood vessels, which rescues circulating HSA from lysosomal degradation. We have conjugated GLP-1 to C34 of native sequence recombinant HSA (rHSA) and two rHSA variants, one with increased and one with decreased binding affinity for human FcRn. We have investigated the impact of conjugation on FcRn binding affinities, GLP-1 potency, and pharmacokinetics, combined with the solution structure of the rHSA variants and GLP-1–albumin conjugates. The solution structures, determined by small-angle X-ray scattering, show the GLP-1 pointing away from the surface of rHSA. Combining the solution structures with the available structural information about the FcRn and GLP-1 receptor obtained from X-ray crystallography, we can explain the observed in vitro and in vivo behavior. We conclude that the conjugation of GLP-1 to rHSA does not affect the interaction between rHSA and FcRn, while the observed decrease in the potency of GLP-1 can be explained by a steric hindrance of binding of GLP-1 to its receptor.